Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-374 5 mg in Healthy Volunteers

Chong Kun Dang

Status and phase: Completed; Phase 1

Conditions: Rheumatoid Arthritis

Treatments: Drug: CKD-374 5mg Tab.; Drug: D569 Tab.

Study type: Interventional

Funder types: Industry

Identifiers

NCT03858725

190BE18031

Details and patient eligibility

About

This study is a randomized, open-label, fasted, single dose, crossover study to evaluate the pharmacokinetic profiles and safety of CKD-374 5 mg in healthy volunteers.

Full description

To healthy subjects of thirty-six (36), following treatments are administered dosing in each period and wash-out period is a minimum of 7 days.

Reference drug: D569 Tab. / Test drug: CKD-374 5mg Tab. Pharmacokinetic blood samples are collected up to 12hrs. The pharmacokinetic characteristics and safety are assessed

Enrollment: 36 patients

Sex: All

Ages: 19 to 54 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Healthy subject older than 19 years and less than 55 years at the screening

2. Individuals who had 17.5 kg/m2 ≤ Body Mass Index(BMI) < 30.5kg/m2 and a total body weight ≥ 55 kg

   * BMI = Weight(kg)/ Height(m)2

3. Individuals without congenital/chronic diseases and without abnormal symptoms or diagnosis based on a medical examination within the last 3 years

4. Individuals who were deemed to be appropriate as study subjects in accordance with the screening results (laboratory tests, vital signs, ECG, chest X-ray etc.)

5. Individuals who signed an informed consent form approved by the IRB of Chonbuk National University Hospital and decided to participate in the study after being fully informed of the study prior to participation, including the objective, content and characteristics of the investigational drug

6. Individuals with the ability and willingness to participate during the study period

Exclusion criteria

1. Individuals with a medical evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurologic or immune disease (excluding simple dental history such as dental calculus, impacted tooth, wisdom tooth, etc.)

2. Individuals with a medical history of gastrointestinal disease (e.g., gullet disease including esophageal achalasia, esophagostenosis, or Crohn's disease) or operations (excluding simple appendectomy, herniotomy, or tooth extraction surgery) that may affect drug absorption

3. Individuals with the following laboratory test results: ALT or AST > 2x the upper limit of the normal range

4. A history of regular alcohol consumption exceeding 210 g/week within the 6 months prior to screening (1 drink (250 mL) of beer (5%) = 10 g; 1 drink (50 mL) of hard liquor (20%) = 8 g; 1 drink (125 mL) of wine (12%) = 12 g)

5. Individuals who smoked more than 20 cigarettes per day within 6 months prior to screening

6. Individuals who had been administered investigational product(s) of other clinical study or bioequivalence study within the 3 months prior to the first dose of this study

7. Individuals with the following vital signs results at screening

   *Individuals who had sitting blood pressure ≥90 mmHg or <140 mmHg (systolic) or ≥90 mmHg or <60 mmHg (diastolic)

8. Individuals with a medical history of significant alcohol abuse or drug abuse within one year prior to the screening

9. Individuals who had taken any drug(s) known as a strong inducer(s) or inhibitor(s) of drug-metabolizing enzymes within 30 days prior to the first dose of investigational product(s)

10. Individuals who had taken prescription or nonprescription drugs within the 10 days prior to the first dose of investigational product(s)

11. Individuals who donated whole blood within the 2 months, or blood components within 1 month prior to the first dose of the investigational product(s)

12. Individuals with severe acute/chronic medical or psychiatric conditions that may increase the risk associated with study participation or investigational product(s) administration, or may interfere with the interpretation of study results

13. Individuals with hypersensitivity to ingredients used in the investigational product(s)

14. Patients with serious infection (e.g., Sepsis) or active infection including localized infection or history of interstitial pneumonia

15. Patients with active tuberculosis or history of tuberculosis

16. Patients with hepatopathy

17. Patients with an absolute neutrophil count (ANC) less than 1000 /ul

18. Patients with an absolute lymphocyte count (ALC) less than 500 /ul

19. Patients who have hemoglobin levels less than 9 g/dL

20. Women who are pregnant or may be pregnant

21. Patients with hereditary diseases of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption etc.

22. Patients with nephropathy (eGFR<60 ml/min/1.73 m2)

23. Individuals who were deemed to be inappropriate to participate in the study by the investigator

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

36 participants in 2 patient groups

D569/CKD-374 5mg

Experimental group

Description:

1. Period 1: D569 Tab. 1T 2. Period 2: CKD-374 5mg Tab. 1T

Treatment:

Drug: CKD-374 5mg Tab.

Drug: D569 Tab.

CKD-374 5mg/D569

Experimental group

Description:

1. Period 1: CKD-374 5mg Tab. 1T 2. Period 2: D569 Tab. 1T

Treatment:

Drug: CKD-374 5mg Tab.

Drug: D569 Tab.